Immunology / Virology & Vaccines

Human liver
#Cancer research #Drug development #Immunology / Virology & Vaccines #Liver disease #Research

Does Hepatitis B virus support the survival and growth of liver cancer? 

Researchers at the Francis Crick Institute and Universidade de Santiago de Compostela have identified how the hepatitis B virus (HBV) can support the survival and growth of liver cancer, with this process starting early in tumour development, in some instances up to 20 years before cancer diagnosis.  Context  Around… Read More

#Cancer Research #News

#Immunology / Virology & Vaccines #Life sciences

Azenta to distribute vaccines to the US Department of Defense 

Brooks Automation’s newly branded Azenta Life Sciences has been contracted by QTC Management to provide the storage and distribution of vaccines to the US Department of Defense.  Context  In early 2021, QTC was awarded the Reserve Health Readiness Program III contract, under which they… Read More

#News #Trending News

#Antibodies #Biotherapeutics #Covid-19 #Data #Funding #Immunology / Virology & Vaccines

Twist Bioscience spins out Covid antibodies into Revelar Biotherapeutics

Twist Bioscience has launched Revelar Biotherapeutics to develop and commercialise an antibody that neutralises all known variants of concern of the SARS-CoV-2 virus in preclinical studies.   In addition, Revelar will have the ability to leverage the antibody discovery and optimisation platform of Twist Biopharma to license additional antibodies for up to five targets over the next four… Read More

#Covid-19 #News

#Immunology / Virology & Vaccines

Valneva to present its vaccine candidate for chikungunya

Valneva presented its chikungunya vaccine candidate, VLA1553, on November 18 and 19, 2021 during the American Society of Tropical Medicine & Hygiene (ASTMH) 2021 Annual Meeting.  Valneva’s Chief Medical Officer, Juan Carlos Jaramillo, presented: “Chikungunya: Phase III Clinical Development of a Single-shot Live-attenuated Vaccine” and Martina… Read More

#News

#Clinical trials #Covid-19 #Drug development #Immunology / Virology & Vaccines

T-cell vaccines may offer “significant benefits” over current Covid-19 vaccines 

Emergex Vaccines has announced that it has received the necessary regulatory approvals to initiate a Phase I clinical trial to evaluate the safety and tolerability of its vaccine candidate for SARS-CoV-2.  The Phase I trial is a double-blind, randomised and comparator-controlled study of two groups of 13 volunteers at high… Read More

#Covid-19 #News

#Cancer research #Drug delivery #Drug development #HPV #Immunology / Virology & Vaccines

HPV vaccine proven to dramatically reduce cervical cancer 

After decades of research, the UK implemented a human papillomavirus (HPV) vaccine programme for teenage girls in 2008. Now, for the first time, a study has shown that the UK HPV vaccine programme works and will save lives, according to research funded by Cancer Research UK.  The vaccine was shown to… Read More

#News

#Drug design #Drug development #Immunology / Virology & Vaccines #mRNA #RNA #Synthetic biology

RNA: a coming-of-age technology for viral vaccines 

Listen to this article on the DDW Podcast: Dr Andy Lane, Commercial Director at The Native Antigen Company, discusses the development of a new generation of vaccine platforms that can be rapidly adapted to novel threats on-demand and at low cost.  Vaccines are one of the… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News #Opinion

#Antivirals #Biotherapeutics #Covid-19 #Immunology / Virology & Vaccines

Beximco Pharma introduces an oral antiviral drug for Covid-19 treatment 

Beximco Pharmaceuticals has launched a generic molnupiravir, an oral antiviral drug for symptomatic Covid-19 patients developed by Merck, Sharp & Dohme (MSD) and Ridgeback Biotherapeutics, following Emergency Use Authorisation by the Directorate General of Drug Administration (DGDA), the regulatory authority in Bangladesh.   Molnupiravir is world’s first oral product to treat symptomatic Covid-19,… Read More

#Covid-19 #News #Trending News

#Covid-19 #Drug design #Drug discovery #Immunology / Virology & Vaccines #Research #T-Cells

T-cell discovery could lead to new type of Covid-19 vaccines 

A study has found that some people are able to clear the Covid-19 virus quickly due to strong immune response from existing T-cells, which could lead to a new generation of vaccine development.   In a study published in Nature, researchers found that individuals with potential exposure to… Read More

#Covid-19 #News #Trending News

Handshake
#Collaboration #Drug development #Immunology / Virology & Vaccines #mRNA

BioNet and BIA Separations collaborate to develop mRNA vaccines 

BioNet and BIA Separations, now part of Sartorius, have developed an optimised mRNA manufacturing process.   BIA’s expertise in chromatographic columns for mRNA purification combined with BioNet’s expertise in the product development of genetic vaccines have, since early 2021, enabled both teams to collaborate on the optimisation and upscale of a high-yield… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines

New consortium to boost Covid-19 vaccine production in South Africa 

The Medicines Patent Pool (MPP), the World Health Organization (WHO), Afrigen Biologics, the Biologicals and Vaccines Institute of Southern Africa (Biovac), the South African Medical Research Council (SAMRC), and Africa Centres for Disease Control and Prevention (Africa CDC) have signed a letter of intent to address the global… Read More

#News

#Immunology / Virology & Vaccines #Research

Vaccine against oral hookworm could save millions 

Researchers at The University of Queensland (UQ) have made a significant breakthrough in the development of a vaccine to prevent hookworm infection – a parasite which causes serious disease in tens of millions of people around the world. Trials of the vaccine candidate in mice indicate that it… Read More

#News

#Covid-19 #EMA #FDA #Immunology / Virology & Vaccines #Pfizer

Pfizer and BioNTech submit data for the vaccination of children 5 to 12 years 

Pfizer and BioNTech have submitted data supporting the vaccination of children 5 to 12 years of age with Comirnaty (Covid-19 mRNA vaccine) to the European Medicines Agency (EMA) for a variation of the Conditional Marketing Authorization (CMA) in the European Union (EU). According to The New York Times, federal regulators evaluated the… Read More

#News